A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis

Article Oncology

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival

Michael Ozga et al.

Summary: This study revealed the association of FISH cytogenetic abnormalities with survival in AL amyloidosis patients, showing that hyperdiploidy has an impact on the prognosis of cardiac AL patients.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

Giovanni Palladini et al.

Summary: AL amyloidosis is caused by abnormal light chains forming amyloid deposits in organs. Chemotherapy aims to suppress the toxic light chains and restore organ function. Next-generation flow cytometry can detect minimal residual disease, which may impact organ response and progression of the disease.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib

Sriram Ravichandran et al.

Summary: The speed of haematologic response has a significant impact on survival outcomes for AL patients, with patients achieving VGPR at 1 month showing significantly better survival rates. Patients with CR and iFLC < 20 mg/l at 1 month also had better survival compared to those with iFLC > 20 mg/l. Early achievement of >= VGPR at 1 month significantly improved survival across all Mayo disease stages.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Letter Medicine, General & Internal